DEXAMETHASONE SODIUM PHOSPHATE - Solution / Drops

Manufacturer
Stat Rx USA
Effective date
2009-10-27
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:07:55

Label at a glance#

ProductDexamethasone Sodium Phosphate
Active ingredientDexamethasone Sodium Phosphate
Label structure11 sections

Label contents#

Full prescribing information#

DESCRIPTION SECTION

DESCRIPTION

Dexamethasone Sodium Phosphate Ophthalmic Solution USP, is a sterile, topical steroid solution. The active ingredient is represented by the following structural formula:

                                                                                                   
Structure Image
Structure Image

                                                                                       

C22H28FNa2O8P

Mol. wt. 516.41

Chemical Name: 9-fluoro-11β, 17-dihydroxy-16α-methyl-21-[phosphonooxy]pregna-1, 4-diene-3,20-dione disodium salt.

Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic. Dexamethasone is a synthetic analog of naturally occurring glucocorticoids (hydrocortisone and cortisone). Dexamethasone sodium phosphate is a water soluble, inorganic ester of dexamethasone. It is approximately three thousand times more soluble at 25°C than hydrocortisone.

Each mL Contains: ACTIVE: Dexamethasone Sodium Phosphate, [equivalent to 1 mg (0.1%) Dexamethasone Phosphate]. INACTIVES: Sodium Citrate, Sodium Borate, Creatinine, Polysorbate 80, Edetate Disodium Dihydrate, Purified Water. Hydrochloric Acid may be added to adjust pH (6.6 - 7.8). PRESERVATIVES ADDED: Sodium Bisulfite 0.1%, Phenylethyl Alcohol 0.25%, Benzalkonium Chloride 0.02%.

CLINICAL PHARMACOLOGY SECTION

CLINICAL PHARMACOLOGY

Dexamethasone sodium phosphate suppresses the inflammatory response to a variety of agents and it probably delays or slows healing. No generally accepted explanation of these steroid properties have been advanced.

INDICATIONS & USAGE SECTION

INDICATIONS AND USAGE

For the treatment of the following conditions:

Ophthalmic

 Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies.

Otic

 Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.

CONTRAINDICATIONS SECTION

CONTRAINDICATIONS

Epithelial herpes simplex keratitis (dendritic keratitis).

Acute infectious stages of vaccinia, varicella and many other viral diseases of the cornea and conjunctiva.

Mycobacterial infection of the eye.

Fungal diseases of ocular or auricular structures.

Hypersensitivity to any component of this product, including sulfites (see WARNINGS).

Perforation of a drum membrane.

WARNINGS SECTION

WARNINGS

Prolonged use may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. In acute purulent conditions of the eye or ear, corticosteroids may mask infection or enhance existing infection. If these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients.

Employment of corticosteroid medication in the treatment of herpes simplex other than epithelial herpes simplex keratitis, in which it is contraindicated, requires great caution; periodic slit-lamp microscopy is essential.

This product contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS SECTION

PRECAUTIONS

General

The possibility of persistent fungal infections of the cornea should be considered after prolonged corticosteroid dosing.

There have been reports of bacterial keratitis associated with the use of multiple dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. (See PRECAUTIONS, Information for Patients.)

ADVERSE REACTIONS SECTION

ADVERSE REACTIONS

Glaucoma with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, perforation of the globe.

Rarely, filtering blebs have been reported when topical steroids have been used following cataract surgery.

Rarely, stinging or burning may occur.

DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION

The duration of treatment will vary with the type of lesion and may extend from a few days to several weeks, according to therapeutic response. Relapses, more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.

Eye

Instill one or two drops of solution into the conjunctival sac every hour during the day and every two hours during the night as initial therapy. When a favorable response is observed, reduce dosage to one drop every four hours. Later, further reduction in dosage to one drop three or four times daily may suffice to control symptoms.

Ear

Clean the aural canal thoroughly and sponge dry. Instill the solution directly into the aural canal. A suggested initial dosage is three or four drops two or three times a day. When a favorable response is obtained, reduce dosage gradually and eventually discontinue.

If preferred, the aural canal may be packed with a gauze wick saturated with solution. Keep the wick moist with the preparation and remove from the ear after 12 to 24 hours. Treatment may be repeated as often as necessary at the discretion of the physician.

HOW SUPPLIED SECTION


HOW SUPPLIED:

Dexamethasone Sodium Phosphate Ophthalmic Solution USP 0.1%, is supplied in a plastic squeeze bottle with a controlled drop tip in the following size: 5 mL - Prod. No. 04407

STERILE OPHTHALMIC SOLUTION

Rx only

FOR USE IN THE EYES OR EARS

Storage Conditions

Store between 15°-30°C (59°-86°F).

DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.

KEEP OUT OF REACH OF CHILDREN.

INFORMATION FOR PATIENTS SECTION

INFORMATION FOR PATIENTS

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.

Patients should also be instructed that ocular preparations, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. (See PRECAUTIONS, General.)

Patients should also be advised that if they develop an intercurrent ocular condition (e.g., trauma, ocular surgery or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.

One of the preservatives in dexamethasone sodium phosphate ophthalmic solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients wearing soft contact lenses should be instructed to wait at least 15 minutes after instilling dexamethasone sodium phosphate ophthalmic solution before they insert their lenses.

Carcinogenesis, mutagenesis, impairment of fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of dexamethasone sodium phosphate ophthalmic solution.

PregnancyPregnancy Category C

Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose.

In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, cleft palate. In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc.

There are no adequate or well-controlled studies in pregnant women. Dexamethasone sodium phosphate ophthalmic solution should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.

Nursing mothers

Topically applied steroids are absorbed systemically. Therefore, because of the potential for serious adverse reactions in nursing infants from dexamethasone sodium phosphate, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric use

Safety and effectiveness in pediatric patients have not been established.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

DEXAMETH SODIUM PHOSPHATE O/S Package Label

Label ImageLabel Image

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
226343dexAMETHasone sodium phosphate 0.1 % Ophthalmic SolutionPSN1
226343dexamethasone phosphate 1 MG/ML Ophthalmic SolutionSCD1
226343dexamethasone sodium phosphate 0.1 % Ophthalmic SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
DEXAMETHASONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
1ea46721-9071-6b81-fd0a-a82bfbb014ecProduct name720250220
525701df-f985-480d-995a-e0ee70c2bdf4Product name520250128
ea50b939-d92a-4100-84f5-1c1089663837Product name220240705
941f67d9-7f03-56d2-750c-36de24f654dbProduct name320221117
d7d46a10-8766-d3c8-ebf2-2ccd9efdcae8Product name220220506
7b2c58e8-5850-4e3e-82e9-b1593b1de761Product name520220210
81e34474-b0a5-434f-8104-25d689efc99eProduct name120200303
05ab9c01-cd9a-4f59-b2e8-ddcb887cac39Product name120190408
0c7dba41-c919-5809-508d-4affe6cfcff2Product name220170817
399647c0-db89-02d1-991c-0c17b584482cProduct name120140508
3e9a6377-704f-dff7-b19f-56c98d40c444Product name120140508
4d2e6ff9-14f5-b84f-c39b-373b005712c1Product name120140508
725d71bf-f956-5cad-e556-fa39cb060dc8Product name120140508
9ea85abb-fa68-5da6-ab60-2c7eef579000Product name120140508
d029211e-5e6b-725f-3696-ac6ff77da222Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
16590-068-052019-10-21C16284748780-1956f9ecf-cb04-621f-e053-dbdaa90a74adDEXAMETHASONE SODIUM PHOSPHATE - Solution / Drops

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
16590-068-05Dexamethasone Sodium Phosphate5 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS51
16590-068-05Dexamethasone Sodium Phosphate1 in 1 CARTONSOLUTION/ DROPS11

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
16590-068DEXAMETHASONE SODIUM PHOSPHATE SOLUTION/ DROPS [STAT RX USA]12 package rows20100212_d3ac05f5-3c52-43a0-99a0-2a0c0f309769.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
16590-068-05ML - Milliliter16590-0684fe05778-653f-4c17-ab52-eb684c3e734412012-07-24
24208-720-02ML - Milliliter24208-7209ed538de-4fde-422a-807f-51e6bec1c7aa12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Dexamethasone Sodium PhosphateACTIVE INGREDIENTAI9376Y64P1
DEXAMETHASONEACTIVE MOIETY7S5I7G3JQL1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
16590-06816590-068-05
24208-720

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
Dexamethasone Sodium PhosphateAI9376Y64PACTIB

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A040069-001DEXAMETHASONE SODIUM PHOSPHATEDEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26d4dbc9d85df4…
2026-10-15 13:18:302026-09A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26c2088c7a36db…
2026-09-14 22:38:342026-08A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-2684e616aacf4f…
2026-08-18 06:07:402026-07A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-2631067a03dcf5…
2025-08-23 18:47 UTC2025-08A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-266a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-2603ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-262680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-265bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-2679d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-261e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-268072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-265c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-265d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-264b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-2674a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-2687673890dc5c…
2021-03-12 10:30 UTC2021-03A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-265aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-268869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-263f01610625f2…
2019-09-15 20:21 UTC2019-09A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26b00525d2431f…
2019-07-19 19:46 UTC2019-07A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-266a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-261c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-269b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-263f0d92c62455…
2023-05-13 08:27 UTC2023-05A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-26053a50430f4f…
2023-01-26 05:58 UTC2023-01A040069-001DEXAMETHASONE SODIUM PHOSPHATEEQ 0.1% PHOSPHATESOLUTION/DROPS / OPHTHALMIC, OTICRS1996-07-263bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Dexamethasone Sodium PhosphateDEXAMETHASONE SODIUM PHOSPHATEBausch & Lomb Incorporated6bdcefbe-51e3-4ca4-afda-5aeca7b6fa732022-08-31Warnings, Adverse reactionsExact identifier
ndc (product): 24208-720
ab150891-9554-497c-a8b1-4757beceaed1d3ac05f5-3c52-43a0-99a0-2a0c0f3097692009-10-27Warnings, Adverse reactionsExact identifier
spl id: ab150891-9554-497c-a8b1-4757beceaed1
spl set id: d3ac05f5-3c52-43a0-99a0-2a0c0f309769

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.